• Oncology
  • Current

Amphivena Therapeutics, in collaboration with Affimed AG, is developing bispecific TandAbs for hematologic malignancies. TandAbs are tetravalent bispecific antibody formats (~100kD) that recruit tumor destroying T cells to tumor cells. By harnessing the immune system, Amphivena’s programs offer potential improvements in efficacy for patients with life-threatening hematologic cancers.

amphivena.com